Clinical efficacy and patient benefits

To date, more than 3000 patients have been included in clinical trials evaluating the efficacy of Cerebrolysin® in Alzheimer's disease and vascular dementia. The longest observation time was 7 months and the treatment regimen was established as a chronic intermittent treatment. Usually, the 4-week treatment cycles were separated by treatment-free periods of 2 or 3 months. Cerebrolysin® was administered 5 days per week intravenously with a daily dosage varying from 10 ml to 60 ml.

Below please find the most important studies of the last years and their key results.

Cerebrolysin® improves cognitive functions in vascular dementia